An example of renal denervation therapy being delivered. A catheter is inserted into the renal artery to ablate the nerves in the vessel wall that regulate vasoconstriction. This leaves the vessel permanently in the widest open position to allow greater blood flow to the kidneys.

May 30, 2018 — Despite the best efforts of clinicians to manage hypertension, it continues to increase and is now reaching epidemic levels worldwide with more than 1 billion patients considered to be suffering from hypertension today. Despite the availability of many safe and effective drugs, the control rates remain unacceptably low. This is mainly due to patient non-compliance in taking hypertension medications. 

Data from the GENETIC-AF trial was presented in a “Late Breaking Clinical Trials” oral presentation at the European Society of Cardiology (ESC) Heart Failure 2018 World Congress, May 26-29 in Vienna, Austria. William T. Abraham, M.D., professor of medicine, physiology and cell biology and director, Division of Cardiovascular Medicine at the Ohio State University presented the data.

Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for calcified coronary artery disease (CAD). The company also announced the first patient enrollment in the DISRUPT CAD II post-market study by Prof. Jonathan Hill, M.D., at King’s College in London.

Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early vessel healing in its target patient population at one month following implantation of the Resolute Onyx drug-eluting stent (DES). The target population contained a high percentage of patients with complex coronary artery disease.

FFR-CT may soon replace invasive angiography for coronary lesion assessment. #EuroPCR 
FFR-CT may soon replace invasive angiography for coronary lesion assessment. #EuroPCR 

May 29, 2018 — Results from the innovative SYNTAX III Revolution Trial [1] underline the effectiveness of evolving noninvasive algorithms for fractional flow reserve assessed through computed tomography (FFR-CT) imaging. The data suggests heart teams should use this imaging-based technology for decision making. The data was presented as a late-breaking study at EuroPCR 2018.   

May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable coronary lesions to improve hard outcomes. Stable lesions include both patients with stable coronary artery disease as well as non-culprit lesions in hemodynamically stabilized acute coronary syndrome (ACS) patients.

May 29, 2018 — The first placebo-controlled trial that looked at how fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) predicts the efficacy of percutaneous coronary intervention (PCI) found angioplasty improved ischemia. The invasive physiology data from 196 patients from the Objective Randomized Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina (ORBITA) Trial was presented as a late-breaking trial at the 2018 EuroPCR conference.

EuroPCR conference live case presentation. PCR late-breaking trials.

Here are the late-breaking trials and other key study presentations from the 2018 EuroPCR conference. This is the annual meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI) of the European Society of Cardiology. It took place May 22-25, 2018 in Paris. The annual meeting attracts more than 10,000 attendees.

Late-breaking Trials at EuroPCR:

M.A. MedAlliance SA has raised $37 million to help develop and commercialize the first sirolimus micro-reservoir drug-coated balloon to treat patients suffering from peripheral artery disease (PAD). The Selution DCB is also intended to treat patients with coronary artery disease (CAD), arteriovenous fistulas (AVF) and grafts (AVG) for end-stage renal disease.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now